In June 2025, the FDA approved neoadjuvant pembrolizumab monotherapy followed by adjuvant pembrolizumab plus radiotherapy with or without cisplatin after surgery and then pembrolizumab monotherapy among patients with PD-L1–positive locally advanced head and neck squamous cell carcinoma.